Preclinical optimization of gp120 entry-antagonists as anti-HIV-1 agents with improved cytotoxicity and ADME properties through rational design, synthesis, and antiviral evaluation.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.9b02149
Abstract: We previously reported a milestone in the optimization of NBD-11021, an HIV-1 gp120 antagonist, by developing a new and novel analog, NBD-14189 (Ref1), which showed antiviral activity against HIV-1HXB2, with an IC50 of 89 nM.… read more here.
Keywords: preclinical optimization; optimization; gp120 entry; adme ... See more keywords